- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04335097
Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation (HSC19)
Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study
Severe acute respiratory syndrome (SARS) SARS-Cov-2 disease (COVID-19) is an infectious disease caused by a coronavirus. The pandemic first described in Wuhan, China, has since spread across the whole world and caused dramatic strain on health care in many countries. Patients infected with the virus mostly report mild to moderate respiratory symptoms like shortness of breath and coughing, and febrile symptoms. It is of paramount importance to preserve health service capacity by identifying those with serious illness without transferring all infected patients to emergency rooms or Hospitals. In addition, it is important to identify seriously ill patients early enough and before they reach a point of deterioration where they can be extremely challenging to handle in both prehospital and hospital environment.
The present study is designed to sample biosensor data from patients treated and observed at home due to mild and moderate SARS-Cov-2 disease. Such a system would be useful, both for the treatment of individual patients as well as for assessing the efficacy and safety of care given to these patients. Investigators intend to improve quality and safety of home care by continuous monitoring and a set of rules for follow-up.
Investigators hypothesized that patients and local health system may benefit from the feedback of a simple monitoring system, which detects changes in respiration, temperature and circulation variables in combination with the patient's subjective experiences of care. Patients may be referred to hospitalization earlier. In the present study we will use live continuous and non-continuous biosensor data to monitor the development of vital parameters for Covid 19 patients compared with patients who are not monitored electronically (standard of care).
Study Overview
Detailed Description
Severe acute respiratory syndrome (SARS) SARS-Cov-2 disease (COVID-19) is an infectious disease caused by a coronavirus. The pandemic first described in Wuhan, China, has since spread across the whole world and caused dramatic strain on health care in many countries. The virus spreads primarily through droplets of saliva or discharge from the nose when an infected person coughs or sneezes.1 Patients infected with the virus mostly report mild to moderate respiratory symptoms like shortness of breath and coughing, and febrile symptoms. Most recover without requiring special treatment. However, older people, and those with underlying medical problems (cardiovascular disease, diabetes, chronic respiratory disease, and cancer) are more likely to develop serious illness.1 Younger patients have been reported with serious illness as well. In the present situation, it is of paramount importance to preserve health service capacity by identifying those with serious illness without transferring all infected patients to emergency rooms or Hospitals. In addition, it is important to identify seriously ill patients early enough and before they reach a point of deterioration where they can be extremely challenging to handle in both prehospital and hospital environment.
The number of subjects with positive test of the virus is increasing and so does the number of patients hospitalized.2 In parallel, most patients with positive test result or typical clinical symptoms are at home with information what to do if their clinical symptom status deteriorates.2 The Norwegian Interaction Reform was implemented in 2012.3 Key elements of the reform are guidance of the health care in the future and identify new directions. Prevention and early efforts are important and this will be achieved by creating co-working arenas for different parts of our health system. More health services must be moved closer to where the inhabitants live and simultaneously strengthening the community health system. New tools for monitoring the well-being of the patients must be developed in order to act early enough to avoid severe deterioration of health status and avoid new hospitalization. This goal has become even more important during the Covid 19 pandemic because the healthcare system is not prepared or built to take care of all these patients in hospitals.
In the local community's wearable and wireless biosensors collecting continuous physiological data (CPD) in real time in order to generate information reflecting the patients' current state is established. This is recognized as welfare technology, and it is a generic term for a heterogeneous group of technologies.4 There are few studies documenting their efficacy, effectiveness and efficiency. One key driver for the development of wearable biosensors is the potential to use CPD to generate real-time, clinically actionable insights from predictive analytics that include early warnings of clinical deterioration and prompts for behavioral changes. The advent of machine learning methods that can detect subtle patterns from large sets of CPD may make this achievable.
Using CPD to guide clinical decisions may be a major advance for patients with chronic diseases and at present time when our health system is put on an extreme stretch. This may drive the evolution from episodic to continuous patient care.
The present study is designed to sample biosensor data from patients treated and observed at home due to mild and moderate SARS-Cov-2 disease. Such a system would be useful, both for the treatment of individual patients as well as for assessing the efficacy and safety of care given to these patients. Investigators intend to improve quality and safety of home care by continuous monitoring and a set of rules for follow-up.
Investigators hypothesized that patients and local health system may benefit from the feedback of a simple monitoring system, which detects changes in respiration, temperature and circulation variables in combination with the patient's subjective experiences of care. Patients may be referred to hospitalization earlier. In the present study investigators will use live continuous and non-continuous biosensor data to monitor the development of vital parameters for Covid 19 patients compared with patients who are not monitored electronically (standard of care).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lillestrom, Norway
- Lillestrom legevakt
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Valid informed consent.
- All Covid 19 positive patients age ≥18 years who are under care at home for Covid 19 infection.
- Patients with typical Covid 19 clinical symptoms where a test has not been taken may also be included if a test later is positive.
- Able to log into internet.
Exclusion Criteria:
- Age <18 years.
- Covid 19 negative.
- Internals in prison.
- Individuals living in special homes due to need of care.
- Refusal of participation.
- Comorbidity that hinder the patient to run the system.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Control
Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service.
|
Sensor that detect vital signs
Other Names:
|
ACTIVE_COMPARATOR: Intervention
Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service.
I addition active reporting of clinical status and continuous vital sign monitoring based on electronic sensors (Welfare technology).
|
Sensor that detect vital signs
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stop home isolation
Time Frame: 1 to 21 days
|
Day during home isolation it was stopped due to hospitalization
|
1 to 21 days
|
NEWS score
Time Frame: 1 to 21 days
|
5 or >3 for one organ system
|
1 to 21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinic at hospitalization
Time Frame: At admittance hospital
|
Relevant vital clinical findings
|
At admittance hospital
|
Symptoms developed
Time Frame: Duration of home isolation
|
Symptoms developed during home isolation
|
Duration of home isolation
|
Relative/peers evaluation of the patient
Time Frame: Duration of home isolation
|
Their description of vital sign development
|
Duration of home isolation
|
Serious of symptoms at admittance hospital
Time Frame: Hospital stay
|
Referred to ICU, intubated, length of stay
|
Hospital stay
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Bodapati RK, Kizer JR, Kop WJ, Kamel H, Stein PK. Addition of 24-Hour Heart Rate Variability Parameters to the Cardiovascular Health Study Stroke Risk Score and Prediction of Incident Stroke: The Cardiovascular Health Study. J Am Heart Assoc. 2017 Jul 21;6(7):e004305. doi: 10.1161/JAHA.116.004305.
- Seamless Healthcare Monitoring Advancements in Wearable, Attachable, and Invisible Devices. Chapter 5 Ballistocardiography.
- The Royal College of Physicians. National Early Warning Score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS. London: RCP; 2017. p. 1-77.
- Williams B, Alberti G, Ball C, et al; Royal College for Physicians: National Early Warning Score (NEWS): Standardising the Assessment of Acute-Illness Severity in the NHS. 2012London, ENG, Royal College of Physicians.
- Meld. St. 16 (2010-2011) Report to the Storting (white paper) Summary - National Health and Care Services Plan. https://www.regjeringen.no/en/dokumenter/meld.-st.-16-2010-2011/id639794/
- Samsudin MI, Liu N, Prabhakar SM, Chong SL, Kit Lye W, Koh ZX, Guo D, Rajesh R, Ho AFW, Ong MEH. A novel heart rate variability based risk prediction model for septic patients presenting to the emergency department. Medicine (Baltimore). 2018 Jun;97(23):e10866. doi: 10.1097/MD.0000000000010866.
- Melillo P, Izzo R, Orrico A, Scala P, Attanasio M, Mirra M, De Luca N, Pecchia L. Automatic prediction of cardiovascular and cerebrovascular events using heart rate variability analysis. PLoS One. 2015 Mar 20;10(3):e0118504. doi: 10.1371/journal.pone.0118504. eCollection 2015.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 127157
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID 19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Biosensors
-
Oslo University HospitalUniversity of the Basque Country (UPV/EHU); Edwards Lifesciences; Stryker Medical and other collaboratorsCompletedHemodynamics | Cardiac | BiosensorsNorway
-
University Hospital, LimogesCompleted
-
Medtronic VascularCompletedCoronary Artery DiseaseKorea, Republic of, Spain, Australia, Hong Kong, United Kingdom, Singapore, Thailand, Belgium, New Zealand, Sweden, France, Switzerland, Netherlands, Italy, Slovakia, Lithuania, Austria, Malaysia, Bulgaria, Ireland, Latvia, Norway, ...
-
Region Örebro CountyBiosensors InternationalWithdrawnStable Angina Pectoris | Unstable Angina Pectoris | Myocardial Infacrtion
-
Yonsei UniversityGangwon Cardiovascular Health Research InstituteTerminated
-
Euro CTO ClubNHS Research and Development; Biosensors International; Asahi Intecc Co., Ltd.CompletedCoronary Occlusion | Dyspnea | Chronic Stable AnginaUnited Kingdom, Spain, France, Germany, Italy, Latvia
-
Seoul National University Bundang HospitalKorea University Anam Hospital; Korea University Guro Hospital; Gachon University... and other collaboratorsCompletedMyocardial Ischemia | Coronary Artery DiseaseKorea, Republic of
-
Dr Peter BarlisBiosensors InternationalUnknownCoronary Heart DiseaseAustralia
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Central Clinical Hospital of the Ministry of Internal...University National Heart HospitalCompleted